CYBN
Cybin Inc.
$8.28
+0.10
(+1.22%)
Mkt Cap
413.02M
Volume
716,528
52W Range
4.81-10.7199
Sector
Healthcare
Beta
0.79
EPS (TTM)
-4.48
P/E Ratio
N/A
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 |
|---|---|
| Revenue | 0 |
| Net Income | (113.14M) |
| EPS | -0.61 |
| Free Cash Flow | (103.27M) |
| FCF / Share | -0.56 |
| Operating CF | (101.30M) |
| Total Assets | 258.62M |
| Total Debt | 0 |
| Cash & Equiv | 135.02M |
| Book Value | 237.20M |
| Return on Equity | -0.48 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.72M) | (24.61M) | (30.58M) | (10.54M) | (57.19M) | (14.82M) |
| EPS | -1.39 | -1.10 | -1.46 | -0.53 | -2.86 | -0.12 |
| Free Cash Flow | (34.92M) | (29.78M) | (22.20M) | (27.43M) | (26.19M) | (27.45M) |
| FCF / Share | -1.44 | -1.33 | -1.06 | -1.41 | -1.31 | -0.22 |
| Operating CF | (34.48M) | (29.55M) | (21.11M) | (27.12M) | (25.85M) | (27.21M) |
| Total Assets | 181.25M | 210.81M | 258.62M | 253.55M | 262.39M | 284.65M |
| Total Debt | 28.89M | 44.50M | 0 | 0 | 133,000 | 212,000 |
| Cash & Equiv | 83.75M | 118.69M | 135.02M | 136.29M | 154.32M | 183.28M |
| Book Value | 139.00M | 151.76M | 237.20M | 240.24M | 255.02M | 279.83M |
| Return on Equity | -0.24 | -0.16 | -0.13 | -0.04 | -0.22 | -0.05 |
CYBN News
No news available for CYBN.